MethylGene Inc. (TSX: MYG) a biopharmaceutical company, today disclosed in a poster presentation, preclinical results further demonstrating the potential of a histone deacetylase (HDAC) inhibitor in human fungal infections at the American Society of Microbiology (ASM) in Orlando, FL. The Company described in vitro properties and the mechanism of action of MG3290, an orally bioavailable HDAC inhibitor that appears selective against specific fungal HDACs.
